Individuals with BRCA1 mutations may experience altered sensitivity to chemotherapeutic agents. For example, they might be more sensitive to DNA-damaging agents like cisplatin, used in cancer therapy, due to their impaired ability to repair DNA. This increased sensitivity can be both a therapeutic advantage and a source of toxicity, necessitating careful management of drug doses.
